About Strongbridge Biopharma PLC (NASDAQ:SBBP)
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:SBBP
- CUSIP: N/A
- Web: www.strongbridgebio.com
- Market Cap: $244.84 million
- Outstanding Shares: 35,335,000
- 50 Day Moving Avg: $6.59
- 200 Day Moving Avg: $5.83
- 52 Week Range: $2.00 - $8.85
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.84
- P/E Growth: 0.00
- Annual Revenue: $1.53 million
- Price / Sales: 142.03
- Book Value: $0.28 per share
- Price / Book: 21.96
- EBITDA: ($39,430,000.00)
- Return on Equity: -83.83%
- Return on Assets: -34.77%
- Debt-to-Equity Ratio: 1.89%
- Current Ratio: 4.63%
- Quick Ratio: 4.46%
- Average Volume: 113,512 shs.
- Beta: 2.71
- Short Ratio: 10.35
Frequently Asked Questions for Strongbridge Biopharma PLC (NASDAQ:SBBP)
What is Strongbridge Biopharma PLC's stock symbol?
Strongbridge Biopharma PLC trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma PLC's earnings last quarter?
Strongbridge Biopharma PLC (NASDAQ:SBBP) posted its earnings results on Monday, August, 7th. The company reported ($0.34) EPS for the quarter, hitting analysts' consensus estimates of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.84 million. View Strongbridge Biopharma PLC's Earnings History.
When will Strongbridge Biopharma PLC make its next earnings announcement?
Where is Strongbridge Biopharma PLC's stock going? Where will Strongbridge Biopharma PLC's stock price be in 2017?
3 brokers have issued 1-year target prices for Strongbridge Biopharma PLC's stock. Their forecasts range from $10.00 to $18.00. On average, they expect Strongbridge Biopharma PLC's stock price to reach $13.33 in the next twelve months. View Analyst Ratings for Strongbridge Biopharma PLC.
Who are some of Strongbridge Biopharma PLC's key competitors?
Some companies that are related to Strongbridge Biopharma PLC include Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Mirna Therapeutics (SYBX), Mereo BioPharma Group PLC (MPH), Fortress Biotech (FBIO), Peregrine Pharmaceuticals (PPHM), Kamada (KMDA), Kadmon Holdings (KDMN), Vericel Corp (VCEL), MediWound (MDWD), KalVista Pharmaceuticals (KALV), Alimera Sciences (ALIM), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT), Chiasma (CHMA) and Cardiome Pharma Corporation (CRME).
Who are Strongbridge Biopharma PLC's key executives?
Strongbridge Biopharma PLC's management team includes the folowing people:
- John H. Johnson, Chairman of the Board
- Matthew Pauls J.D., Chief Executive Officer, Director
- A. Brian Davis, Chief Financial Officer
- Stephen J. Long, Chief Legal Officer
- Robert Lutz, Chief Business Officer
- Ruth Thieroff-Ekerdt M.D., Chief Medical Officer
- Richard S. Kollender, Director
- Garheng Kong M.D. Ph.D., Director
- Marten Steen, Director
- Hilde H Steineger, Director
Who owns Strongbridge Biopharma PLC stock?
How do I buy Strongbridge Biopharma PLC stock?
Shares of Strongbridge Biopharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Strongbridge Biopharma PLC's stock price today?
MarketBeat Community Rating for Strongbridge Biopharma PLC (NASDAQ SBBP)MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Strongbridge Biopharma PLC stock can currently be purchased for approximately $6.15.
Consensus Ratings for Strongbridge Biopharma PLC (NASDAQ:SBBP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$13.33 (116.80% upside)|Consensus Price Target History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Analysts' Ratings History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/10/2017||Oppenheimer Holdings, Inc.||Initiated Coverage||Outperform||$12.00||High|
|5/17/2017||HC Wainwright||Reiterated Rating||Buy||Low|
|12/28/2016||JMP Securities||Reiterated Rating||Outperform||$10.00||N/A|
|2/3/2016||Roth Capital||Initiated Coverage||Buy||$12.00||N/A|
|12/10/2015||Janney Montgomery Scott||Initiated Coverage||Buy||$19.00||N/A|
|12/7/2015||Stifel Nicolaus||Reiterated Rating||Buy||N/A|
Earnings History for Strongbridge Biopharma PLC (NASDAQ:SBBP)Earnings History by Quarter for Strongbridge Biopharma PLC (NASDAQ SBBP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/22/2017|| || || || || || || || |
|8/7/2017||Q2 2017||($0.34)||($0.34)||$0.84 million||$1.53 million||View||Listen|
Earnings Estimates for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Current Year EPS Consensus Estimate: $-2.66 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS
Dividend History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Latest Headlines for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Loading headlines, please wait.
Strongbridge Biopharma PLC (SBBP) Chart for Sunday, October, 22, 2017